ALK and crizotinib: after the honeymoon... what else? Resistance mechanisms and new therapies to overcome it Review

Rolfo, Christian, Passiglia, Francesco, Castiglia, Marta et al. (2014). ALK and crizotinib: after the honeymoon... what else? Resistance mechanisms and new therapies to overcome it . Translational Lung Cancer Research, 3(4), 250-261. 10.3978/j.issn.2218-6751.2014.03.01

cited authors

  • Rolfo, Christian; Passiglia, Francesco; Castiglia, Marta; Raez, Luis E; Germonpre, Paul; Gil-Bazo, Ignacio; Zwaenepoel, Karen; De Wilde, Annemieke; Bronte, Giuseppe; Russo, Antonio; Van Meerbeeck, Jan P; Van Schil, Paul; Pauwels, Patrick

authors

publication date

  • August 1, 2014

published in

keywords

  • ALK inhibitors
  • ALK rearrangements
  • ALK/EGFR INHIBITOR AP26113
  • ANAPLASTIC LYMPHOMA KINASE
  • CELL LUNG-CANCER
  • CLINICAL-RESPONSE
  • EML4-ALK
  • FUSION GENE
  • HSP90 INHIBITOR
  • IMMUNOHISTOCHEMISTRY
  • Life Sciences & Biomedicine
  • NSCLC
  • NSCLC PATIENTS
  • Oncology
  • PHASE-II
  • Respiratory System
  • Science & Technology
  • resistance

Digital Object Identifier (DOI)

start page

  • 250

end page

  • 261

volume

  • 3

issue

  • 4